Tarek I Hassanein, MD, an expert hepatologist and clinical investigator, presents for DURECT Corporation as Key Opinion Leader or “KOL” on the results of a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH). Consider attending the...